ABBV: The Post-Humira Growth Story Is Already Here

Revenue grew 24.5% from Q1 to Q4. That's not the profile of a company losing its franchise — it's a company rebuilding one.

Q4 2025 gross margin hit 84% — up dramatically from 70% in Q1. The swing reflects the product mix shift: Humira biosimilar competition compresses margins on that legacy product, while Skyrizi and Rinvoq carry premium pricing with manufacturing scale benefits that improve over time.

Net income was $1.82 billion in Q4 versus just $186 million in Q3. The Q3 number was depressed by a $2.68 billion charge in other expenses — likely acquisition-related impairment. Strip out the noise: operating income was $5.8 billion in Q4, a 35% operating margin.

Trailing twelve-month GAAP EPS was just $2.37. But operating cash flow tells the truth: $2.93 per share in Q4 alone, with operating cash flow to net income quality ratio of 2.87x. The cash machine runs regardless of what GAAP says.

AbbVie's balance sheet is the bear case that keeps value investors awake. Total debt stands at approximately $69 billion — a legacy of the $63 billion Allergan acquisition. Shareholder equity is negative at -$1.81 per share, and the current ratio of 0.67 sits below 1.0.

But pharma balance sheets don't work like industrial companies. AbbVie's debt is serviceable because cash flow is predictable: $2.93 per share in Q4 operating cash flow against $0.18 in capex gives an FCF per share of $2.75. Annualised, that's roughly $11 per share in free cash flow — a 5% FCF yield at current prices.

Interest coverage of 8.9x is healthy. The dividend yield of 0.72% with a payout ratio that looks inflated on GAAP (160%) is actually well-covered by adjusted earnings. AbbVie has increased its dividend every year since spinning off from Abbott in 2013 — 53 consecutive years including the Abbott era.

Humira was the best-selling drug in pharmaceutical history at peak sales of $21.2 billion. Replacing it seemed impossible. AbbVie did it with two drugs.

Skyrizi (risankizumab) targets IL-23 for psoriasis and Crohn's disease. Rinvoq (upadacitinib) is a JAK inhibitor for rheumatoid arthritis, atopic dermatitis, and ulcerative colitis. Together, they're on a combined annual run rate north of $18 billion based on recent quarterly trajectories — and both are still gaining indication approvals.

The pipeline extends beyond immunology. AbbVie's neuroscience portfolio includes migraine treatments and potential Alzheimer's candidates. The aesthetics business (Botox, from Allergan) provides diversification outside pharma. R&D spending ran $2.58 billion in Q4 — 15.5% of revenue — funding 90+ programmes in clinical development.

The competitive moat is the immunology franchise depth. Unlike single-product biotech companies, AbbVie can lose share in one indication and offset it in another. The platform scales.

AbbVie reports Q1 2026 earnings on May 1. Key catalysts through the year include new indication approvals for Skyrizi and Rinvoq, pipeline readouts in neuroscience, and potential M&A as the company deploys its growing free cash flow.

Analyst consensus projects quarterly EPS reaching $4.26-$4.69 by 2028 — implying annual adjusted EPS approaching $17. At the current $221.82 price, that's a forward PE of roughly 13x on 2028 estimates. For a company growing revenue at 20%+ annually with 84% gross margins, that multiple is a disconnect.

The stock slipped below its 50-day moving average on March 13 but remains well above the 200-day SMA. The 52-week range of $164-$245 suggests the current $222 level is mid-range — neither overextended nor at a technical bottom.

The legal overhang from drug pricing lawsuits (a U.S. appeals court revived overcharging claims on March 17) represents headline risk but not existential threat. AbbVie has navigated pricing controversies throughout Humira's life without material financial impact.